Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be
able to replace blood-forming cells that were destroyed by chemotherapy and radiation
therapy. Sometimes the transplanted cells from a donor can make an immune response against
the body's normal cells. Giving busulfan and melphalan with or without antithymocyte globulin
before transplant and cyclosporine with methylprednisolone or methotrexate after transplant
may stop this from happening.
PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in
treating young patients with relapsed or refractory solid tumors.